IGKV2D-29 and Parkinson disease: Antagonism of A2A, P2X1, P2X7 and P2Y6 receptor subtypes is a promising weapon against PD via various ways: reducing l-DOPA induced dyskinesia, influencing neuroinflammation, preventing α-synuclein aggregation, reducing microglia activation.